News articles about argenx SE – American Depositary Shares (NASDAQ:ARGX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. argenx SE – American Depositary Shares earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.9561796900633 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of argenx SE – American Depositary Shares (ARGX) opened at $70.52 on Tuesday. argenx SE – American Depositary Shares has a 52 week low of $17.33 and a 52 week high of $71.40.
A number of research analysts have commented on ARGX shares. Zacks Investment Research upgraded argenx SE – American Depositary Shares from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research note on Tuesday, October 24th. Wedbush restated an “outperform” rating and set a $41.00 price target (up from $26.00) on shares of argenx SE – American Depositary Shares in a research note on Thursday, November 16th. They noted that the move was a valuation call. Finally, Piper Jaffray Companies upped their price target on argenx SE – American Depositary Shares to $100.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 19th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $50.00.
TRADEMARK VIOLATION NOTICE: “argenx SE – American Depositary Shares (NASDAQ:ARGX) Receiving Somewhat Favorable News Coverage, Study Finds” was originally published by BBNS and is owned by of BBNS. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://baseballnewssource.com/markets/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-argenx-se-american-depositary-shares-argx-stock-price/1819503.html.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Receive News & Ratings for argenx SE - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx SE - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.